Pharmacokinetic Study of Buagafuran Capsules in Participants With Hepatic Impairment and Normal Hepatic Function

This study adopts a non-randomized, open label, parallel, single-dose design to evaluate the safety and pharmacokinetic characteristics of Buagafuran capsules in participants with hepatic impairment. This study enrolled 24 participants, both male and female. Three experimental groups were set up, with Day1 taking 30 mg Buagafuran capsules on an empty stomach in the morning.Participants can leave on Day3.